Inclisiran is a small interfering RNA therapy. The use of inclisiran for lowering down the blood cholesterol levels has still not been approved by any regulatory body. However, the results of the clinical study promise good results. The study Orion constitutes Phases III trials designed to evaluate the efficacy of the drug. The therapy lowers down the lower low-density lipoprotein (LDL) cholesterol – also known as LDL-C or bad cholesterol.
Blackstone Life Sciences and Ferring Pharmaceuticals have
collaborated to jointly develop Ferring’s late-stage bladder cancer therapy
candidate investing USD 570 Mn.
Under the terms of the agreement, Blackstone has agreed to invest an amount of USD 400 Million while Ferring will invest up to USD 170 Million.
The joint agreement will help the manufacturing and
commercialization of the drug, nadogaragene firadenovec and help secure the
global rights. Upon the approval, FerGene, a new subsidiary of Ferring will
have the sole market authorization.
The gene therapy is indicated for high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). Currently, the drug is in Phase III clinical trials.
The main treatments for when the cancer cells are found only
in the bladder’s inner lining (non-muscle- invasive bladder cancer) are
surgery, immunotherapy, and intravesical chemotherapy. Surgery—on its own or
combined with other treatments—is used in most cases.
Other pharma players like Sesen Bio, Altor BioScience, TARIS Biomedical, and many more are advancing the Non-Muscle Invasive Bladder Cancer (NMIBC) treatment market.
Alexion Pharmaceuticals has recently received a nod from
Japan’s Health, Labour and Welfare Ministry (MHLW) for its drug Soliris (eculizumab).
The drug has received the recommendation for the expanded
use to prevent relapse in anti-aquaporin-4 (AQP4) antibody-positive
neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica.
The drug is the first drug to receive approval in Japan. The trials PREVENT revealed promising results of the drug to prolong time to the first relapse and reduce relapse risk. However, the drug is already approved to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults and atypical hemolytic uremic syndrome (aHUS) in children.
At present, there exists no cure for Neuromyelitis Optica (NMO) and the existing treatment regimen revolves around relieving symptoms and prevention of frequent recurrences.
Key players, such as Alexion Pharma, Chugai Pharmaceutical/ Roche, and Viela Bio are involved in developing therapies for NMOSD. The launch of emerging therapy, such as Soliris (Alexion Pharma), Satralizumab (SA237) (Chugai Pharmaceutical/ Roche) and MEDI-551 (Viela Bio) will significantly impact the NMOSD market during the study period (2016-2027).
